Search results for "pharmacy"

showing 10 items of 705 documents

Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study.

2016

Aims.In recent years several warnings have been issued by regulatory authorities on the risk of electrocardiogram abnormalities in individuals exposed to psychotropic drugs. As a consequence of these warnings, monitoring of the QT interval corrected for heart rate (QTc) has become increasingly common. This study was conducted to measure the frequency of QTc prolongation in unselected psychiatric patients, and to document the associated factors using a cross-sectional approach.Method.The study was carried out in 35 Italian psychiatric services that are part of the STAR (Servizi Territoriali Associati per la Ricerca) Network, a research group established to produce scientific knowledge by col…

AdultMalemedicine.medical_specialtyPsychotropic drugsEpidemiologymedicine.medical_treatmentLong QT syndromeAntidepressantDrug overdoseAdverse effectQT intervalAntipsychotic03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsPsychotropic drugmedicinePrevalenceHumanscardiovascular diseasesAntipsychoticAdverse effectPsychiatrySettore MED/25 - PsichiatriaPolypharmacybusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health; Environmental and Occupational Health; Psychiatry and Mental HealthOriginal Articlesmedicine.diseaseAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030227 psychiatrySubstance abuseLong QT SyndromeCross-Sectional StudiesItalyPsychiatry and Mental HealthPolypharmacyAripiprazoleFemalePublic HealthbusinessAntidepressant; adverse effect; antipsychotic; psychotropic drugsAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Adult; Antipsychotic Agents; Cross-Sectional Studies; Electrocardiography; Female; Humans; Italy; Long QT Syndrome; Male; Prevalence; Risk Factors; Polypharmacy; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsEpidemiology and psychiatric sciences
researchProduct

Cataracts and statins. A disproportionality analysis using data from VigiBase.

2019

The basis of the association between statin use and cataract has been explored using the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) through January 2019. The reporting odds ratios (RORs) as a measure of disproportionality for reported cataracts and individual statins have been calculated. Subgroup analyses according statin lipophilicity, sex, and age groups have been performed. Moreover, RORs have been calculated for non-statin lipid lowering drugs. An increased disproportionality have been found for most individual statins lovastatin: [ROR: 14.80, 95% confidence interval (CI): 13.30, 16.46)], atorvastatin (ROR: 3…

AdultMalemedicine.medical_specialtyStatinAdolescentmedicine.drug_classAtorvastatin010501 environmental sciencesToxicology030226 pharmacology & pharmacy01 natural sciencesRisk AssessmentCataract03 medical and health sciencesPharmacovigilanceYoung Adult0302 clinical medicineEzetimibeInternal medicinemedicineOdds RatioAdverse Drug Reaction Reporting SystemsHumansRosuvastatinChild0105 earth and related environmental sciencesAgedAged 80 and overbusiness.industryIncidenceGeneral MedicineOdds ratioMiddle AgedSimvastatinFemaleDrug MonitoringHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatinRegulatory toxicology and pharmacology : RTP
researchProduct

Pharmaceutical validation as a process of improving the quality of antineoplastic treatment

2006

Objective. To quantify the improvement added by standardization of pharmaceutical validation (PV) of antineoplastic treatment to the processes of prescription and preparation of the pharmacotherapeutic sequence, in terms of prevention and reduction of medication errors (ME). Design. Prospective cohort study during two years (from 2001-2002) for oncohaematologic patients (inpatients and outpatients) that compared the percentage of medication errors detected and resolved and the number of medication errors with potential clinical significance (severity value ≥4) intercepted during PV in both years. Results. During the PV processes, 202 ME were identified and resolved, which is the equivalent…

AdultMalemedicine.medical_specialtyTime FactorsAntineoplastic AgentsMedical Oncology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineInternal medicineHumansMedication ErrorsMedicinePharmacology (medical)Clinical significanceProspective StudiesMedical prescriptionProspective cohort studyAgedAged 80 and overInpatientsbusiness.industryHematologyMiddle AgedPrognosisSurgeryOncologyPharmaceutical Services030220 oncology & carcinogenesisFemalePatient CarebusinessHospital UnitsTotal Quality ManagementJournal of Oncology Pharmacy Practice
researchProduct

Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone p…

2018

BACKGROUND Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. METHOD Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two gr…

AdultMalemedicine.medical_specialtyaripiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; neurology; neurology (clinical); psychiatry and mental health; pharmacology (medical)Global Assessment of FunctioningAripiprazoleSchizoaffective disorderPharmacyOutcome Assessment (Health Care)03 medical and health sciencesYoung Adult0302 clinical medicineglobal assessment of functioningInternal medicineOutcome Assessment Health CarePaliperidone PalmitatemedicineHumansPharmacology (medical)aripiprazole monohydratearipiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult; Outcome Assessment (Health Care)Paliperidone Palmitatebusiness.industrylong-acting injectable antipsychoticsMiddle Agedschizoaffective disordermedicine.disease030227 psychiatryPsychiatry and Mental healthNeurologyPsychotic DisordersSchizophreniaDelayed-Action PreparationsSettore SECS-P/03 - Scienza delle FinanzeSchizophreniaChronic schizophreniaAripiprazoleFemaleNeurology (clinical)business030217 neurology & neurosurgeryDiagnosis of schizophreniamedicine.drugAntipsychotic AgentsHuman psychopharmacology
researchProduct

Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report

2019

Abstract Background Long-acting injectable (LAI) antipsychotics for psychotic disorders provide advantages in treatment compliance, but data on their use in pregnancy are very limited. We present a clinical case of aripiprazole LAI use in pregnancy. Case presentation A 43-year-old woman diagnosed with bipolar disorder, with several relapses due to treatment interruption while trying to conceive. Finally, aripiprazole LAI treatment was planned by mutual agreement between doctor and the patient, who took aripiprazole LAI before and during pregnancy. She gave birth at 40 weeks to a 3500 g baby girl with no congenital malformations, who was healthy at 5 months after delivery. Conclusion As far …

AdultPediatricsmedicine.medical_specialtyTime FactorsBipolar disordermedicine.medical_treatmentvirusesAripiprazoleCase Report030226 pharmacology & pharmacyInjections IntramuscularAntipsychotic03 medical and health sciences0302 clinical medicineimmune system diseasesPregnancylcsh:RA1190-1270medicineHumansPharmacology (medical)Bipolar disorderAntipsychoticlcsh:Toxicology. PoisonsPharmacologyDosage FormsPregnancybusiness.industrylcsh:RM1-950Pregnancy Outcomevirus diseasesCongenital malformationsmedicine.diseasePregnancy ComplicationsLong actinglcsh:Therapeutics. PharmacologyTreatment interruptionLong-acting injectable aripiprazoleAripiprazoleFemaleClinical casebusinessmedicine.drugAntipsychotic AgentsFollow-Up StudiesBMC Pharmacology and Toxicology
researchProduct

Targeted Hybrid Nanocarriers as a System Enhancing the Skin Structure

2021

The skin is constantly exposed to external and internal factors that disturb its function. In this work, two nanosystems-levan nanoparticles and a surfactin-stabilized nanoemulsion were preserved (tested for microbial growth) and characterized (size, polydispersity, Zeta potential, and stability). The nanosystems were introduced in the model formulations-cream, tonic, and gel, and confirmed by TEM. The analysis showed that nanoemulsion has a spherical morphology and size 220–300 nm, while levan nanoparticles had irregular shapes independently of the use of matrix and with particle size (130–260 nm). Additionally, we examined the antiradical effect of levan nanoparticles and nanoemulsion in …

AdultskinMaterials scienceDPPHDispersitySkin CreamnanoemulsionPharmaceutical ScienceNanoparticleformulationMicrobial Sensitivity Tests02 engineering and technology030226 pharmacology & pharmacySkin DiscolorationsurfactinArticleAnalytical Chemistrylcsh:QD241-44103 medical and health scienceschemistry.chemical_compound0302 clinical medicinelcsh:Organic chemistryIn vivoDrug DiscoveryZeta potentialHumansPhysical and Theoretical ChemistryDrug CarriersBacteriaanti-agingOrganic ChemistryMiddle Aged021001 nanoscience & nanotechnologyDynamic Light ScatteringlevanFructansSkin AgingchemistryChemistry (miscellaneous)Molecular MedicineEmulsionsFemalenanoparticlesParticle sizeNanocarriers0210 nano-technologyBiomedical engineeringMolecules
researchProduct

Multimorbidity and polypharmacy in the elderly: Lessons from REPOSI

2014

none 10 no The dramatic demographic changes that are occurring in the third millennium are modifying the mission of generalist professionals such as primary care physicians and internists. Multiple chronic diseases and the related prescription of multiple medications are becoming typical problems and present many challenges. Unfortunately, the available evidence regarding the efficacy of medications has been generated by clinical trials involving patients completely different from those currently admitted to internal medicine: much younger, affected by a single disease and managed in a highly controlled research environment. Because only registries can provide information on drug effectiven…

Adverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Aged; Aged; 80 and over; Female; Humans; Internal Medicine; Italy; Male; Registries; Societies; Medical; Comorbidity; Geriatrics; Polypharmacy; Internal Medicine; Emergency MedicineMalemedicine.medical_specialtyAgingmedia_common.quotation_subjectDrug prescriptionMEDLINEAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Aged; Aged 80 and over; Female; Humans; Internal Medicine; Italy; Male; Registries; Societies Medical; Comorbidity; Geriatrics; Polypharmacy; Internal Medicine; Emergency MedicineDiseaseComorbidityAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; PolypharmacyelderlyAdverse drug effectsPromotion (rank)MedicalmedicineAdverse drug effect80 and overInternal MedicineHumansRegistriesMedical prescriptionmedia_commonAgedGeriatricsPolypharmacyAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Emergency Medicine; Internal MedicineMultimorbidity Polypharmacy Aging Drug prescription Multidimensional evaluation Adverse drug effectsMultidimensional evaluationbusiness.industrySettore MED/09 - MEDICINA INTERNAMultimorbiditymedicine.diseaseComorbidityelderly multimorbidity polypharmacyClinical trialItalyGeriatricsFamily medicinePolypharmacyEmergency MedicineFemaleMedical emergencyAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Internal Medicine; Emergency MedicinebusinessSocietiesmultimorbidity; polypharmacy; aging; drug prescription; multidimensional evaluation; adverse drug effectsMultimorbidity; Polypharmacy; Aging; Drug prescription; Multidimensional evaluation
researchProduct

Drug-drug interactions in a cohort of hospitalized elderly patients.

2013

PurposeThe aim of this study is to assess the prevalence of patients exposed to potentially severe drug-drug interactions (DDIs) at hospital admission and discharge and the related risk of in-hospital mortality and adverse clinical events, readmission, and all-cause mortality at 3months. MethodsThis cross-sectional, prospective study was held in 70 Italian internal medicine and geriatric wards. Potentially severe DDIs at hospital admission and discharge; risk of in-hospital mortality and of adverse clinical events, readmission, and all-cause mortality at 3-month follow-up. ResultsAmong 2712 patients aged 65years or older recruited at hospital admission, 1642 (60.5\%) were exposed to at leas…

Aged 80 and overMaledrug interactionpharmacoepidemiologyDrug-Related Side Effects and Adverse ReactionsmortalityCohort StudiesHospitalizationCross-Sectional StudiesItalyMultivariate AnalysisPolypharmacyHumansDrug InteractionsFemaleAged
researchProduct

Neurofisiología y envejecimiento. Concepto y bases fisiopatológicas del deterioro cognitivo

2016

Brain ageing is produced by various morphological, biochemical, metabolic and circulatory changes, which are reflected in functional changes, whose impact depends on the presence or absence of cognitive impairment. Because of brain plasticity, together with redundancy of the distinct cerebral circuits, age- related deterioration of the brain at various levels does not always translate into loss of brain function. However, when the damage exceeds certain thresholds, there is age-related cognitive impairment, which increases the risk of developing various neurodegenerative diseases such as Alzheimer disease. Genetics, together with lifestyle, diet, and environmental factors, etc, can trigger …

AgingMedicine (miscellaneous)medicine.disease030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineAgeing030220 oncology & carcinogenesisNeuroplasticitymedicineGeriatrics and GerontologyAlzheimer's diseasePsychologyCognitive impairmentNeuroscienceBrain functionRevista Española de Geriatría y Gerontología
researchProduct

Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA.

2017

The Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) proposed six Action Groups. After almost three years of activity, many achievements have been obtained through commitments or collaborative work of the Action Groups. However, they have often worked in silos and, consequently, synergies between Action Groups have been proposed to strengthen the triple win of the EIP on AHA. The paper presents the methodology and current status of the Task Force on EIP on AHA synergies. Synergies are in line with the Action Groups' new Renovated Action Plan (2016-2018) to ensure that their future objectives are coherent and fully connected. The …

AgingProcess managementGeriatrics & GerontologyEuropean Innovation Partnership on Active and Healthy Ageing polypharmacy education falls frailty integrated care citizen empowerment chronic respiratory diseasesHealth BehaviorChronic respiratory diseasesPARTNERSHIPCoaching[SHS]Humanities and Social Sciences0302 clinical medicineSurveys and Questionnaires80 and overMedicineCooperative BehaviorComputingMilieux_MISCELLANEOUSInterventionsmedia_commonintegrated careAged 80 and over:Enginyeria biomèdica [Àrees temàtiques de la UPC]Multiple Chronic ConditionOrganizational Innovation3. Good healthCHRONIC RESPIRATORY-DISEASESHealthAction planGeneral partnershipFallsHEALTHPartnershipINTERVENTIONSHumanmedia_common.quotation_subjectfallFrail ElderlyEuropean Continental Ancestry GroupBioengineeringWhite PeopleEducation03 medical and health sciencesEUROPEAN-UNIONActive and Healthy Ageingmedia_common.cataloged_instanceHumansBioenginyeriaEuropean unionAgedScience & TechnologyNutrition & DieteticsPreventionPREVENTIONCitizen empowerment030228 respiratory systemAction (philosophy)European Innovation Partnership on Active and Healthy Ageing; polypharmacy; education; falls; frailty; integrated care; citizen empowerment; chronic respiratory diseases; Accidental Falls; Aged; Aged 80 and over; Chronic Disease; Cooperative Behavior; Europe; Frail Elderly; Humans; Multiple Chronic Conditions; Organizational Innovation; Polypharmacy; Surveys and Questionnaires; Aging; European Continental Ancestry Group; Health BehaviorGeriatrics and GerontologyGerontologySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]OPERATIONAL DEFINITIONEMPOWERMENTMedicine (miscellaneous)Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyChronic respiratory-diseasesAllergic rhinitisQUALITY-OF-LIFEEuropean-UnionNutrition and DieteticSurveys and Questionnaire030212 general & internal medicineMultiple Chronic ConditionsEmpowermenteducationNutrition and DieteticsFrailtyAccidental FallIntegrated careALLERGIC RHINITISEuropeSettore MED/42EmpowermentLife Sciences & BiomedicinefrailtyEuropean Innovation Partnership on Active and Healthy AgeingJournal ArticleMETIS-318216IR-101708Responsible Research and Innovationbusiness.industrychronic respiratory diseaseIntegrated careOperational definition3121 General medicine internal medicine and other clinical medicineChronic DiseasePolypharmacycitizen empowermentAccidental Fallschronic respiratory diseases; citizen empowerment; education; European Innovation Partnership on Active and Healthy Ageing; falls; frailty; integrated care; polypharmacy; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyQuality-of-lifebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe journal of nutrition, healthaging
researchProduct